Abstract
In late 2011, Burn et al. published updated results on the CAPP2 trial in The Lancet. CAPP2 investigated the effects of daily aspirin on patients with Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer. The two related articles in this issue provide an overview of CAPP2 as well as a perspective on the challenges of interpreting a large prospective trial.
